Journal
GUT MICROBES
Volume 12, Issue 1, Pages -Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/19490976.2020.1813533
Keywords
Clostridioides difficile; endolysin; bacteriophage; antimicrobials; clostridioides difficileinfections; antibiotics; novel therapy
Categories
Funding
- European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant [754535]
Ask authors/readers for more resources
Clostridioides difficileis the leading cause of health-care-associated infection throughout the developed world and contributes significantly to patient morbidity and mortality. Typically, antibiotics are used for the primary treatment ofC. difficileinfections (CDIs), but they are not universally effective for all ribotypes and can result in antibiotic resistance and recurrent infection, while also disrupting the microbiota. Novel targeted therapeutics are urgently needed to combat CDI. Bacteriophage-derived endolysins are required to disrupt the bacterial cell wall of their target bacteria and are possible alternatives to antibiotics. These lytic proteins could potentially replace or augment antibiotics in CDI treatment. We discuss candidate therapeutic lysins derived from phages/prophages ofC. difficileand their potential as antimicrobials against CDI. Additionally, we review the antibacterial potential of some recently identified homologues ofC. difficileendolysins. Finally, the challenges of endolysins are considered with respect to the development of novel lysin-based therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available